Intensity Therapeutics (INTS) Interest Coverage Ratio (2022 - 2026)
Intensity Therapeutics' (INTS) quarterly Interest Coverage Ratio came in at 22.35 in Q1 2026, up 88.8% YoY from 11.84 in Q1 2025, and up 87.19% on a QoQ basis from 174.44 in Q4 2025.
Intensity Therapeutics (INTS) Interest Coverage Ratio (2022 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 5 years of Interest Coverage Ratio data on file, last reported at 22.35 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 88.8% year-over-year to 22.35 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 98.27 (up 66.46% YoY) and the FY2025 annual result came in at 176.06, down 17119.48% from the prior year.
- Interest Coverage Ratio rose to 22.35 in Q1 2026, from 174.44 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 3203.0 in Q4 2024 to a low of 1581.0 in Q1 2024.
- A 5-year average of 21.74 and a median of 69.36 in 2025 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2023 — Interest Coverage Ratio soared 98.08% — and 2024, when it slumped 10650.24%.
- Tracing INTS's Interest Coverage Ratio over 5 years: stood at 39.7 in 2022, then rose by 26.18% to 29.31 in 2023, then soared by 11029.55% to 3203.0 in 2024, then sank by 105.45% to 174.44 in 2025, then jumped by 87.19% to 22.35 in 2026.
- The last three Interest Coverage Ratio figures came in at 22.35 (Q1 2026), 174.44 (Q4 2025), and 20.86 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Intensity Therapeutics | 12.99 Mn | 12.99 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -29.65 |
| Mar 31, 2026 | -22.35 |
| Dec 31, 2025 | -174.44 |
| Sep 30, 2025 | -20.86 |
| Jun 30, 2025 | -69.36 |
| Mar 31, 2025 | -199.65 |
| Dec 31, 2024 | 3,203.00 |
| Sep 30, 2024 | -210.00 |
| Jun 30, 2024 | -266.79 |
| Mar 31, 2024 | -1,581.00 |
| Sep 30, 2023 | -29.31 |
| Jun 30, 2023 | -2.48 |
| Mar 31, 2023 | -15.11 |
| Dec 31, 2022 | -39.70 |
| Sep 30, 2022 | -116.90 |
| Jun 30, 2022 | -129.01 |